CONGRESS|#EHA2021| Meletios Dimopolous, discussed treatment for R/R myeloma pts. Rd based regimen should be given to pts receiving bortezomib upfront w/o lenolidomide/daratumumab. Lenalidomide refractory pts could get PomVD, DaraKd, IsakKd/Dara Vd #mmsm #myeloma @uoaofficial pic.twitter.com/K8vXLK5rmN
— Multiple Myeloma Hub (@MM_Hub) June 14, 2021